Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brodalumab: 4-Year US Pharmacovigilance Report.
Lebwohl M, Koo J, Leonardi C, Armstrong A, Rawnsley N, Goehring E, Jacobson A. Lebwohl M, et al. J Drugs Dermatol. 2023 Apr 1;22(4):419-422. doi: 10.36849/JDD.7344. J Drugs Dermatol. 2023. PMID: 37026879
J Drugs Dermatol. 2023;22(4) doi:10.36849/JDD.7344 Citation: Lebwohl M, Koo J, Leonardi C, et al. Brodalumab: 4-Year US pharmacovigilance report. J Drugs Dermatol. 2023;22(4):419-422. doi:10.36849/JDD.7344....
J Drugs Dermatol. 2023;22(4) doi:10.36849/JDD.7344 Citation: Lebwohl M, Koo J, Leonardi C, et al. Brodalumab: 4-Year US pharma …
Development of the Generalized Pustular Psoriasis Clinical Assessment Tool.
Garg A, Noe MH, Anadkat MJ, Armstrong A, Bhutani T, Farberg A, Han G, Hawkes JE, Lebwohl M, Rekhtman S, Song EJ, Strunk A, Duffin KC. Garg A, et al. Among authors: lebwohl m. J Am Acad Dermatol. 2024 Jan;90(1):192-195. doi: 10.1016/j.jaad.2023.08.096. Epub 2023 Sep 20. J Am Acad Dermatol. 2024. PMID: 37739266 No abstract available.
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
Kim BS, Bissonnette R, Nograles K, Munera C, Shah N, Jebara A, Cirulli J, Goncalves J, Lebwohl M; KOMFORT Trial Investigators. Kim BS, et al. Among authors: lebwohl m. N Engl J Med. 2023 Feb 9;388(6):511-517. doi: 10.1056/NEJMoa2210699. N Engl J Med. 2023. PMID: 36780675 Clinical Trial.
The Association between Obesity and Efficacy of Psoriasis Therapies: An Expert Consensus Panel.
Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb AB, Gold LS, Korman NJ, Lio P, Merola J, Rosmarin D, Rosenberg A, Van Voorhees A, Lebwohl M. Burshtein J, et al. Among authors: lebwohl m. J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03390-5. doi: 10.1016/j.jaad.2024.12.016. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39709077
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
Harris JE, Pandya AG, Lebwohl M, Hamzavi IH, Grimes P, Gottlieb AB, Sofen HL, Moore AY, Wang M, Kornacki D, Butler K, Rosmarin D. Harris JE, et al. Among authors: lebwohl m. Skin Health Dis. 2024 Aug 7;4(6):e404. doi: 10.1002/ski2.404. eCollection 2024 Dec. Skin Health Dis. 2024. PMID: 39624731 Free PMC article. No abstract available.
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
Armstrong AW, Lebwohl M, Warren RB, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp KA, Kisa RM, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo MJ, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Armstrong AW, et al. Among authors: lebwohl m. JAMA Dermatol. 2024 Nov 27. doi: 10.1001/jamadermatol.2024.4688. Online ahead of print. JAMA Dermatol. 2024. PMID: 39602111
751 results